Palisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary

• Palisade Bio Inc PALI.OQ reported a quarterly adjusted loss of 58 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.32. The mean expectation of three analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -62 cents to -48 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Palisade Bio Inc's reported EPS for the quarter was a loss of 58 cents​.

• The company reported a quarterly loss of $2.78 million.

• Palisade Bio Inc shares had risen by 10.3% this quarter and lost 54.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Palisade Bio Inc is $8.00, about 90.6% above its last closing price of $0.75

This summary was machine generated from LSEG data August 13 at 03:36 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)